Heterocyclic Compounds And Their Use As Aldosterone Synthase Inhibitors
The application relates to novel heterocyclic compounds of the general formula (I) in which R, R 1 , R 2 , X, Y, Z and n have the meanings defined in the description, to a process for their preparation and to the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors.
1 . Compound of the general formula
in which
X is C;
Y is C or, if Z is C, is also N;
Z is C or a bond;
R is hydrogen, C 1 -C 8 -alkyl, C 1 -C 8 -alkoxy-C 0 -C 4 -alkyl, halogen or trifluoromethyl;
R 1 is unsaturated heterocyclyl-C 0 -C 4 -alkyl, which radical is unsubstituted or substituted by 1-4 C 1 -C 8 -alkyl, C 0 -C 8 -alkylcarbonyl, C 1 -C 8 -alkylsulfonyl, halogen, cyano, oxo, tri-C 1 -C 4 -alkylsilyl, trifluoromethoxy, trifluoromethyl, C 0 -C 8 -alkylcarbonylamino, C 0 -C 8 -alkylcarbonyl-C 1 -C 8 -alkylamino, carbamoyl, mono- or di-C 1 -C 8 -alkylaminocarbonyl, carboxy-C 0 -C 4 -alkyl, C 1 -C 8 -alkoxy, C 1 -C 8 -alkoxycarbonyl, heterocyclyl or aryl, where heterocyclyl or aryl is unsubstituted or substituted by 1-4 C 1 -C 8 -alkyl, C 0 -C 8 -alkylcarbonyl, C 1 -C 8 -alkylsulfonyl, halogen, cyano, oxo, tri-C 1 -C 4 -alkylsilyl, trifluoromethoxy, trifluoromethyl, C 0 -C 8 -alkylcarbonylamino, C 0 -C 8 -alkylcarbonyl-C 1 -C 8 -alkylamino, carbamoyl, mono- or di-C 1 -C 8 -alkylaminocarbonyl, carboxy-C 0 -C 4 -alkyl, C 1 -C 8 -alkoxy or Cl-C 8 -alkoxycarbonyl;
R 2 a) is hydrogen; or
b) is C 1 -C 8 -alkyl, C 3 -C 8 -cycloalkyl, halogen, carboxy-C 1 -C 4 -alkyl, C 1 -C 4 -alkoxycarbonyl-C 1 -C 4 -alkyl, C 0 -C 4 -alkylcarbonyl, aryl-C 0 -C 4 -alkyl or unsaturated heterocyclyl-C 1 -C 4 -alkyl, which radicals are unsubstituted or substituted by 1-4 C 1 -C 8 -alkyl, C 0 -C 8 -alkylcarbonyl, C 1 -C 8 -alkylsulfonyl, halogen, cyano, oxo, tri-C 1 -C 4 -alkylsilyl, trifluoromethoxy, trifluoromethyl, C 0 -C 8 -alkylcarbonylamino, C 0 -C 8 -alkylcarbonyl-C 1 -C 8 -alkylamino, carbamoyl, mono- or di-C 1 -C 8 -alkylaminocarbonyl, carboxy-C 0 -C 4 -alkyl, C 1 -C 8 -alkoxy, C 1 -C 8 -alkoxycarbonyl, heterocyclyl or aryl, where heterocyclyl or aryl is unsubstituted or substituted by 1-4 C 1 -C 8 -alkyl, C 0 -C 8 -alkylcarbonyl, C 1 -C 8 -alkylsulfonyl, halogen, cyano, oxo, tri-C 1 -C 4 -alkylsilyl, trifluoromethoxy, trifluoromethyl, C 0 -C 8 -alkylcarbonylamino, C 0 -C 8 -alkylcarbonyl-C 1 -C 8 -alkylamino, carbamoyl, mono- or di-C 1 -C 8 -alkylaminocarbonyl, carboxy-C 0 -C 4 -alkyl, C 1 -C 8 -alkoxy or C 1 -C 8 -alkoxycarbonyl;
n is a number 0, 1 or 2;
and the salts thereof, preferably the pharmaceutically usable salts thereof,
and its salt, prodrug or compound in which one or more atoms are replaced by their stable, nonradioactive isotopes, in particular, pharmaceutically usable salt;
where, if Z is a bond and R 2 is hydrogen, R 1 is not carbazole, benzoimidazolyl, benzotriazolyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl; or
if Z is a bond, R 2 is hydrogen and R 1 is an unsaturated, monocyclic S-containing-heterocycle radical, these radicals are substituted by C 0 -C 8 -alkylcarbonyl, cyano, aryl or heterocyclyl.
2 . Compound according to claim 1 , characterized in that it corresponds to the general formula
where the meanings of the substituents R, R 1 and R 2 are as indicated for compounds of the formula (I) according to claim 1 .
3 . Compound according to claim 1 , where R is hydrogen, C 1 -C 8 -alkyl, halogen or trifluoromethyl.
4 . Compound according to claim 1 , where R 1 is pyrrolyl, furanyl, oxazolyl, thiazolyl, indolyl, indazolyl, benzofuranyl, benzothiophenyl or isoquinolinyl, which radicals are unsubstituted or substituted by 1-4 C 1 -C 8 -alkyl, C 0 -C 8 -alkylcarbonyl, halogen, cyano, oxo, trifluoromethyl, C 0 -C 8 -alkylcarbonylamino, C 0 -C 8 -alkylcarbonyl-C 1 -C 8 -alkylamino, carbamoyl, mono- or di-C 1 -C 8 -alkylaminocarbonyl, carboxy-C 0 -C 4 -alkyl, C 1 -C 8 -alkoxy, C 1 -C 8 -alkoxycarbonyl, heterocyclyl or aryl.
5 . Compound according to claim 1 , where R 2 is hydrogen, halogen, C 1 -C 8 -alkyl, aryl-C 0 -C 4 -alkyl or unsaturated heterocyclyl-C 0 -C 4 -alkyl.
6 . Compound according to claim 1 , where n is a number 0 or 1.
7 . Compound according to claim 1 , where
R is hydrogen or methyl;
R 1 is pyrrolyl, furanyl, oxazolyl, thiazolyl, indolyl, indazolyl, benzofuranyl, benzothiophenyl or isoquinolinyl, which radicals are unsubstituted or substituted by 1-4 C 1 -C 8 -alkyl, C 0 -C 8 -alkylcarbonyl, halogen, cyano, oxo, trifluoromethyl, C 0 -C 8 -alkylcarbonylamino, C 0 -C 8 -alkylcarbonyl-C 1 -C 8 -alkylamino, carbamoyl, mono- or di-C 1 -C 8 -alkylaminocarbonyl, carboxy-C 0 -C 4 -alkyl, C 1 -C 8 -alkoxy, C 1 -C 8 -alkoxycarbonyl, heterocyclyl or aryl; and
R 2 is hydrogen or C 1 -C 3 -alkyl.
8 - 10 . (canceled)
11 . Method for the prevention, for delaying the progression or for the treatment of pathological states which are caused or partly caused by hyperaldosteronism, where a therapeutically effective amount of a compound of the general formula (I) according to claim 1 is used.
12 . Method for the prevention, for delaying the progression or for the treatment of pathological states which are caused or partly caused by excessive cortisol release, where a therapeutically effective amount of a compound of the general formula (I) according to claim 1 is used.
13 . Pharmaceutical product comprising a compound of the general formula (I) according to claim 1 , and conventional excipients.
14 . Pharmaceutical combination in the form of a product or of a kit composed of individual components consisting a) of a compound of the general formula (I) according to claim 1 , and b) at least one pharmaceutical form whose active ingredient has a blood pressure-lowering, an inotropic, a metabolic or a lipid-lowering effect.
15 . Compound according to claim 2 , where R is hydrogen, C 1 -C 8 -alkyl, halogen or trifluoromethyl.
16 . Compound according to claim 2 , where R 1 is pyrrolyl, furanyl, oxazolyl, thiazolyl, indolyl, indazolyl, benzofuranyl, benzothiophenyl or isoquinolinyl, which radicals are unsubstituted or substituted by 1-4 C 1 -C 8 -alkyl, C 0 -C 8 -alkylcarbonyl, halogen, cyano, oxo, trifluoromethyl, C 0 -C 8 -alkylcarbonylamino, C 0 -C 8 -alkylcarbonyl-C 1 -C 8 -alkylamino, carbamoyl, mono- or di- C 1 -C 8 -alkylaminocarbonyl, carboxy-C 0 -C 4 -alkyl, C 1 -C 8 -alkoxy, C 1 -C 8 -alkoxycarbonyl, heterocyclyl or aryl.
17 . Compound according to claim 2 , where R 2 is hydrogen, halogen, C 1 -C 8 -alkyl, aryl-C 0 -C 4 -alkyl or unsaturated heterocyclyl-C 0 -C 4 -alkyl.
18 . Compound according to claim 2 , where
R is hydrogen or methyl;
R 1 is pyrrolyl, furanyl, oxazolyl, thiazolyl, indolyl, indazolyl, benzofuranyl, benzothiophenyl or isoquinolinyl, which radicals are unsubstituted or substituted by 1-4 C 1 -C 8 -alkyl, C 0 -C 8 -alkylcarbonyl, halogen, cyano, oxo, trifluoromethyl, C 0 -C 8 -alkylcarbonylamino, C 0 -C 8 -alkylcarbonyl-C 1 -C 8 -alkylamino, carbamoyl, mono- or di-C 1 -C 8 -alkylaminocarbonyl, carboxy-C 0 -C 4 -alkyl, C 1 -C 8 -alkoxy, C 1 -C 8 -alkoxycarbonyl, heterocyclyl or aryl; and
R 2 is hydrogen or C 1 -C 3 -alkyl.
19 . Method for the prevention, for delaying the progression or for the treatment of pathological states which are caused or partly caused by hyperaldosteronism, where a therapeutically effective amount of a compound of the general formula (Ia) according to claim 2 is used.
20 . Method for the prevention, for delaying the progression or for the treatment of pathological states which are caused or partly caused by excessive cortisol release, where a therapeutically effective amount of a compound of the general formula (Ia) according to claim 2 is used.
21 . Pharmaceutical product comprising a compound of the general formula (Ia) according to claim 2 , and conventional excipients.
22 . Pharmaceutical combination in the form of a product or of a kit composed of individual components consisting a) of a compound of the general formula (Ia) according to claim 2 , and b) at least one pharmaceutical form whose active ingredient has a blood pressure-lowering, an inotropic, a metabolic or a lipid-lowering effect.